An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Status Not yet recruiting

Clinical Trial Summary

This phase I trial studies the side effects of 124I-hJAA-F11, and evaluates how well it works in diagnosing lung cancer. 124I-hJAA-F11 uses a known radioactive substance used in imaging called iodine 124 (124I). hJAA-F11 is an experimental (investigational) antibody that is currently being evaluated as a potential treatment for lung cancer. In animal studies, hJAA-F11 has shown anti-tumor activity against tumors bearing the Thomsen-Friedenreich antigen that is found in over 90% of lung cancers. 124I-hJAA-F11 has the 124I radioactive dye attached to this investigational antibody, which may be a potential tool for imaging-based diagnosis of lung cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To evaluate the safety and diagnostic efficacy of 124I-hJAA-F11 in detecting lung cancer. SECONDARY OBJECTIVES: I. To assess the development of anti-drug antibodies following administration of 124I-hJAAF11. II. To characterize concordance in lesions characterized by 124I-hJAA-F11-based positron emission tomography/computed tomography (PET/CT) compared to standard of care FDG (fluorodeoxyglucose)-PET. III. To perform exploratory biomarker analyses based on conventional tissue and liquid-based platforms. OUTLINE: Patients receive 124I-hJAA-F11 intravenously (IV) on day 0. Patients then undergo PET/CT on day 1 (20-28 hours post 124I-hJAA-F11), day 2 (48-96 hours post 124I-hJAA-F11), day 5-6 (120-144 hours post 124I-hJAA-F11), and day 7-8 (168-192 hours post 124I-hJAA-F11). Patients also undergo FDG PET/CT during screening and undergo blood sample collection throughout the trial. After completion of the study intervention, patients are followed up at day 8-14, weeks 4 and 8, and at 6 and 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06427369
Study type	Interventional
Source	Roswell Park Cancer Institute
Contact	ASK RPCI
Phone	1-877-275-7724
Email	Askrpci@roswellpark.org
Status	Not yet recruiting
Phase	Phase 1
Start date	September 1, 2024
Completion date	September 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04989283` - Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer	Phase 2
Recruiting	`NCT05106374` - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Terminated	`NCT03707925` - Bronchoscopic Laser Ablation of Peripheral Lung Tumors	N/A
Active, not recruiting	`NCT04013542` - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Phase 1
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Recruiting	`NCT04073745` - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT05830058` - Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT03637816` - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer	Phase 2/Phase 3
Recruiting	`NCT04298606` - A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence	Early Phase 1
Recruiting	`NCT06122064` - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer	N/A
Recruiting	`NCT05802186` - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study	N/A
Recruiting	`NCT03634241` - Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study	Phase 2
Recruiting	`NCT04314401` - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting	`NCT05493566` - Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Early Phase 1
Suspended	`NCT05501665` - Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Phase 1/Phase 2
Withdrawn	`NCT04061590` - Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT06225427` - Gilteritinib for the Treatment of ALK NSCLC	Phase 1
Withdrawn	`NCT04085081` - Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers	N/A
Active, not recruiting	`NCT03939481` - Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
Recruiting	`NCT05672108` - Transarterial Chemoembolization for the Treatment of Lung Cancer	Phase 2